TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 150 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,168,779 | -41.3% | 690,020 | +0.9% | 0.00% | -50.0% |
| Q2 2023 | $10,508,283 | -32.4% | 684,133 | -1.0% | 0.00% | -33.3% |
| Q1 2023 | $15,538,363 | +16.0% | 690,901 | +8.5% | 0.00% | 0.0% |
| Q4 2022 | $13,390,326 | -14.0% | 636,725 | +0.7% | 0.00% | -25.0% |
| Q3 2022 | $15,576,000 | +1.0% | 632,145 | -0.7% | 0.00% | +33.3% |
| Q2 2022 | $15,422,000 | -4.4% | 636,514 | +1.6% | 0.00% | 0.0% |
| Q1 2022 | $16,139,000 | -6.5% | 626,260 | +12.7% | 0.00% | 0.0% |
| Q4 2021 | $17,252,000 | +26.9% | 555,796 | -0.9% | 0.00% | +50.0% |
| Q3 2021 | $13,595,000 | +50.6% | 560,615 | -9.4% | 0.00% | 0.0% |
| Q2 2021 | $9,028,000 | -43.6% | 618,745 | -3.5% | 0.00% | -33.3% |
| Q1 2021 | $16,004,000 | -4.5% | 640,921 | +4.2% | 0.00% | 0.0% |
| Q4 2020 | $16,758,000 | – | 614,897 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |